TY - JOUR
T1 - Survival Without Disability to Age 5 Years After Neonatal Caffeine Therapy for Apnea of Prematurity
AU - Schmidt, Barbara
AU - Anderson, Peter J.
AU - Doyle, Lex W.
AU - Dewey, Deborah
AU - Grunau, Ruth E.
AU - Asztalos, Elizabeth V.
AU - Davis, Peter G.
AU - Tin, Win
AU - Moddemann, Diane
AU - Solimano, Alfonso
AU - Ohlsson, Arne
AU - Barrington, Keith J.
AU - Caffeine for Apnea of Prematurity (CAP)
AU - van der Hoeven, Mark
AU - Roberts, Robin S.
PY - 2012/1/18
Y1 - 2012/1/18
N2 - Very preterm infants are prone to apnea and have an increased risk of death or disability. Caffeine therapy for apnea of prematurity reduces the rates of cerebral palsy and cognitive delay at 18 months of age.To determine whether neonatal caffeine therapy has lasting benefits or newly apparent risks at early school age.Five-year follow-up from 2005 to 2011 in 31 of 35 academic hospitals in Canada, Australia, Europe, and Israel, where 1932 of 2006 participants (96.3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004. A total of 1640 children (84.9%) with birth weights of 500 to 1250 g had adequate data for the main outcome at 5 years.Combined outcome of death or survival to 5 years with 1 or more of motor impairment (defined as a Gross Motor Function Classification System level of 3 to 5), cognitive impairment (defined as a Full Scale IQ
AB - Very preterm infants are prone to apnea and have an increased risk of death or disability. Caffeine therapy for apnea of prematurity reduces the rates of cerebral palsy and cognitive delay at 18 months of age.To determine whether neonatal caffeine therapy has lasting benefits or newly apparent risks at early school age.Five-year follow-up from 2005 to 2011 in 31 of 35 academic hospitals in Canada, Australia, Europe, and Israel, where 1932 of 2006 participants (96.3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004. A total of 1640 children (84.9%) with birth weights of 500 to 1250 g had adequate data for the main outcome at 5 years.Combined outcome of death or survival to 5 years with 1 or more of motor impairment (defined as a Gross Motor Function Classification System level of 3 to 5), cognitive impairment (defined as a Full Scale IQ
U2 - 10.1001/jama.2011.2024
DO - 10.1001/jama.2011.2024
M3 - Article
C2 - 22253394
SN - 0098-7484
VL - 307
SP - 275
EP - 282
JO - JAMA-Journal of the American Medical Association
JF - JAMA-Journal of the American Medical Association
IS - 3
ER -